Drug Trial Radar · NCT07098663
Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Aug 12, 2025
Primary completion
Jan 19, 2026
Study completion Apr 17, 2026
Sponsor
- Lead sponsor
- Mankind Pharma LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Emerald Clinical Inc.
- First posted
- Aug 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this intervention study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MKP10241 in obese participants with and without T2DM in 3 parts. The main parameters it aims to answers are : 1. Does food effects the pharmacokinetic parameters following a single dose of MKP10241 in healthy participants? 2. Will multiple ascending doses of MKP10241 in obese participants with or without T2DM characterize changes in the plasma pharmacokinetic profile and pharmacodynamic effects? 3. What treatment emergent adverse events or discontinuation is experienced following single and multiple ascending doses of MKP10241 in healthy and obese participants with or without T2DM? This study will be compared against a placebo which is matched in appearance to MKP10241 at dosage strengths. Participants will: 1. Part 1: Take MKP10241 400 mg or Placebo on Day 1 and Day 8. Part 2: Take MKP10241 200 mg, 300 mg and 400 mg or Placebo daily from Day 1 to Day 28 Part 3: Take MKP10241 300 mg and 400 mg or Placebo daily from Day 1 to Day 28 2. Visit the clinical research unit for dose administration, admission or follow up. 3. Will be monitored by the Safety Monitoring Committee.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Food Effect
- Safety and Tolerability
- Obesity
Interventions
MKP10241Drug
Oral liquid suspension of unit dose strength 6.6 mg/mL
PlaceboDrug
Oral liquid suspension matched in appearance to MKP10241 at dosage strengths
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Food effect of single dose of MKP10241 on Maximum concentration of drug (Cmax)Time frame: 18 days
- Part 1 - Food effect of single dose of MKP10241 on Apparent total clearance of drug (CL/F)Time frame: 18 days
- Part 1 - Food effect of single dose of MKP10241 on Time to maximum concentration (Tmax)Time frame: 18 days
- Part 1 - Food effect of single dose of MKP10241 on elimination half life (t1/2 )Time frame: 18 days
- Part 1 - Food effect of single dose of MKP10241 on lag time (Tlag)Time frame: 18 days
- Part 1 - Food effect of single dose of MKP10241 on Apparent Volume of distribution of drug (V/F)Time frame: 18 days
- Part 1 - Food effect of single dose of MKP10241 on Area under the curve from time 0 to 24hrs - AUC (0-24h)Time frame: 18 days
- Part 1 - Food effect of single dose of MKP10241 on AUC(0-last)Time frame: 18 days
- Part 1 - Food effect of single dose of MKP10241 on AUC(0-inf)Time frame: 18 days
- Part 2 - To evaluate the incidence of treatment emergent adverse events and participant tolerance of MKP10241 following multiple doses in obese participantsTime frame: 35 days
- Part 3 - To evaluate the incidence of treatment emergent adverse events and participant tolerance of MKP10241 following multiple doses in obese participants with T2DM.Time frame: 35 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Veritus Research
Bayswater, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.